Company Filing History:
1 out of 832,891 Years Active: 2002
Title: Ilva Frolov: Innovator in Recombinant Alphavirus-Based Vectors
Introduction
Ilva Frolov is a notable inventor based in St. Louis, MO (US). He has made significant contributions to the field of biotechnology, particularly in the development of recombinant alphavirus-based vectors. His work has implications for various applications in genetic research and therapeutic development.
Latest Patents
Frolov holds a patent for "Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis." This patent describes isolated nucleic acid molecules that comprise an alphavirus nonstructural protein gene. When incorporated into a recombinant alphavirus particle, these molecules exhibit a reduced level of vector-specific RNA synthesis compared to wild-type. However, they maintain the same or greater level of proteins encoded by RNA transcribed from the viral junction region promoter, compared to a wild-type recombinant alphavirus particle. The patent also includes RNA vector replicons, alphavirus vector constructs, and eukaryotic layered vector initiation systems that contain these nucleic acid molecules.
Career Highlights
Throughout his career, Ilva Frolov has focused on advancing the understanding and application of alphavirus vectors in molecular biology. His innovative approaches have led to breakthroughs that enhance the efficiency of gene delivery systems. Frolov's work is recognized for its potential to improve therapeutic strategies in various medical fields.
Collaborations
Frolov has collaborated with esteemed colleagues, including Thomas W Dubensky, Jr. and John M Polo. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and expertise, further enhancing the impact of their research.
Conclusion
Ilva Frolov's contributions to the field of recombinant alphavirus-based vectors highlight his role as an influential inventor. His patent and collaborative efforts reflect a commitment to advancing biotechnology and its applications.